Supplement to australian pharma JUNE 2013

First Page		Document Content
Date: 2013-09-22 21:05:17 Blindness Diabetes Glaucoma Diabetic retinopathy Optic neuropathy Optometry Bevacizumab Presumed ocular histoplasmosis syndrome Diabetic neuropathy Medicine Health Ophthalmology		Supplement to australian pharma JUNE 2013 Add to Reading List Source URL: www.optometrists.asn.au Download Document from Source Website File Size: 3,45 MB Share Document on Facebook

	A Avastin versus Lucentis: Why It Matters lthough Lucentis is a remarkably safe and effective treatment for exudative macular degeneration, it could cost our health care system over $9 billion, which DocID: 12Y6g - View Document
	Supplement to australian pharma JUNE 2013 DocID: 10GGY - View Document
	MD Research News Issue 200 Tuesday 30 September, 2014 This free weekly bulletin lists the latest published research articles on macular degeneration (MD) and some DocID: 10cRM - View Document
	Microsoft Word - Wet AMD_HS Panel_May 2010 _eng_ FINAL.doc DocID: Zk2W - View Document
	Supplement to australian pharma JUNE 2013 DocID: Ycn7 - View Document